Antibody directed enzymes revive anti-cancer prodrugs concept
Open Access
- 1 November 1987
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 56 (5), 531-532
- https://doi.org/10.1038/bjc.1987.237
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cellsBiochemical and Biophysical Research Communications, 1986
- ANTI-IDIOTYPIC AND NON-ANTI-INDIOTYPIC ANTIBODIES TO OKT3 ARISING DESPITE INTENSE IMMUNOSUPPRESSIONTransplantation, 1986
- The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitroBritish Journal of Cancer, 1986
- Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers—Where do we go from here?British Journal of Cancer, 1983
- Protease-activated “prodrugs” for cancer chemotherapyProceedings of the National Academy of Sciences, 1980
- Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the walker tumourInternational Journal of Cancer, 1971
- 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256Biochemical Pharmacology, 1969
- Reduction of Cytotoxic Azo Compounds by Hydrazine and by the Xanthine Oxidase–Xanthine SystemNature, 1955